Patents by Inventor Andrew H.-J. Wang

Andrew H.-J. Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230233699
    Abstract: The present invention relates to oligonucleotide conjugates and preparation and applications thereof. In particular, the present invention relates to an oligonucleotide conjugated to a biomolecule (e.g. an antibody) and/or an agent of interest (e.g. a drug). In certain embodiments, the oligonucleotide of the present invention is a hybridized complex of a single strand oligonucleotide carrying a biomolecule and a complementary strand oligonucleotide bearing an agent of interest where the hybridized nucleotide segment acts as a linker to link the biomolecule and the agent of interest in one molecule.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 27, 2023
    Applicant: ACADEMIA SINICA
    Inventors: Andrew H.-J. WANG, Cheng-Chung LEE, Nai-Shu HSU, Wen-Chih KUO
  • Publication number: 20230220065
    Abstract: Disclosed herein are anti-IL-1? antibodies capable of binding to human IL-1? and blocking its biological activities. Also provided herein are pharmaceutical compositions comprising the anti-IL-1? antibodies and therapeutic and diagnostic uses of such antibodies.
    Type: Application
    Filed: June 15, 2021
    Publication date: July 13, 2023
    Applicant: ACADEMIA SINICA
    Inventors: Andrew H.-J. WANG, Wen-Chih KUO, Cheng-Chung LEE, An-Suei YANG
  • Patent number: 9856483
    Abstract: Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (QC) with E45Q mutation, so as to autonomously produce a target protein having a N-terminal pyroglutamate (pGlu) residue in a host cell. The first fusion protein is composed of a maltose binding protein (MBP) and a tobacco etch virus protease (TEVP); and the second fusion protein includes in sequence, a thioredoxin, a S-tag, a linker having a TEVP recognition site therein, a target protein, and a (His)-6-tag. The second fusion protein is cleaved by the TEVP that is expressed by the first fusion protein, and then catalyzed by QC with E45Q mutation so as to autonomously produce the target protein having a N-terminal pGlu residue in the host cell.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: January 2, 2018
    Inventors: Andrew H. -J. Wang, Kai-Fa Huang, Yan-Ping Shih
  • Publication number: 20160273015
    Abstract: Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (QC) with E45Q mutation, so as to autonomously produce a target protein having a N-terminal pyroglutamate (pGlu) residue in a host cell. The first fusion protein is composed of a maltose binding protein (MBP) and a tobacco etch virus protease (TEVP); and the second fusion protein includes in sequence, a thioredoxin, a S-tag, a linker having a TEVP recognition site therein, a target protein, and a (His)-6-tag. The second fusion protein is cleaved by the TEVP that is expressed by the first fusion protein, and then catalyzed by QC with E45Q mutation so as to autonomously produce the target protein having a N-terminal pGlu residue in the host cell.
    Type: Application
    Filed: March 18, 2015
    Publication date: September 22, 2016
    Inventors: Andrew H. -J. Wang, Kai-Fa Huang, Yan-Ping Shih
  • Patent number: 9067985
    Abstract: An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a T7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to Asn94 of SEQ ID NO: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant Haloarcula marismortui bacteriorhodopsin/D94N (HmBRI/D94N) or a Haloquadratum walsbyi bacteriorhodopsin (HwBR); b) a target membrane protein; and c) a T7 promoter, operably linked to the mutant HmBRI/D94N or HwBR and the target membrane protein. Host cells comprising the expression vector or the fusion membrane protein expression system and methods of using the same are also disclosed.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: June 30, 2015
    Assignee: ACADEMIA SINICA
    Inventors: Andrew H.-J. Wang, Min-Feng Hsu, Chii-Shen Yang, Hsu-Yuang Fu
  • Publication number: 20140099667
    Abstract: An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a T7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to Asn94 of SEQ ID NO: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant Haloarcula marismortui bacteriorhodopsin/D94N (HmBRI/D94N) or a Haloquadratum walsbyi bacteriorhodopsin (HwBR); b) a target membrane protein; and c) a T7 promoter, operably linked to the mutant HmBRI/D94N or HwBR and the target membrane protein. Host cells comprising the expression vector or the fusion membrane protein expression system and methods of using the same are also disclosed.
    Type: Application
    Filed: September 30, 2013
    Publication date: April 10, 2014
    Applicant: Academia Sinica
    Inventors: Andrew H.-J. WANG, Min-Feng` Hsu, Chii-Shen Yang, Hsu-Yuang Fu
  • Publication number: 20130101571
    Abstract: Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants.
    Type: Application
    Filed: March 23, 2012
    Publication date: April 25, 2013
    Applicant: Academia Sinica
    Inventors: Andrew H-J. Wang, Shiuan-Woei Lin Wu, Fu-Chuo Peng, Che-An Wu
  • Publication number: 20120244138
    Abstract: Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 27, 2012
    Applicant: Academia Sinica
    Inventors: Andrew H-J. Wang, Shiuan-Woei Lin Wu, Fu-Chuo Peng, Che-An Wu
  • Patent number: 7892771
    Abstract: A crystalline structure of glutaminyl cyclase (QC) is described. Also described are the methods of preparing the crystalline structure of QC and the methods for identifying candidate inhibitors of QC. In addition, a structural basis for the rational design or identification of new inhibitors that may be used to treat QC-associated disorders is also described.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: February 22, 2011
    Assignee: Academia Sinica
    Inventors: Andrew H.-J. Wang, Kai-Fa Huang
  • Patent number: 7846719
    Abstract: A vector for expressing a soluble glutaminyl cyclase (QC) in bacterial cells is described. The vector contains a sequence encoding a fusion QC, which has a fusion protein tag selected from a Nus protein tag or a thioredoxin (Trx) tag, a QC, and a linker having at least one (His)x-tag between the QC and the fusion protein tag, in which x is an integer of at least 6. Methods for expressing a soluble glutaminyl cyclase (QC) by the vector are also described.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: December 7, 2010
    Assignee: Academia Sinica
    Inventors: Andrew H.-J. Wang, Kai-Fa Huang
  • Publication number: 20100035300
    Abstract: A cis-TEVP fusion protein including a TEVP protease, a TEVP cleavage site and a target protein provide a platform for expression of the target protein. A trans-TEVP fusion protein including a TEVP cleavage site and a target protein, the amino-terminal portion of the target protein adjacent to the C-terminal portion of the TEVP cleavage site, the amino acidic residue in position P2 of the TEVP cleavage site being a Valine also produces the target protein by the same process. A cis-TEVP fusion protein system comprising the first fusion protein and a suitable host cell; a trans-TEVP fusion protein system comprising the second fusion protein and a suitable host cell; associated methods to produce target proteins, and kits of parts are also disclosed herein.
    Type: Application
    Filed: February 27, 2006
    Publication date: February 11, 2010
    Inventors: Andrew H.-J. Wang, Ting-Fang Wang, Yan-Ping Shih, Hui-Chung Wu, Su-Ming Hu
  • Publication number: 20090203045
    Abstract: A crystalline structure of glutaminyl cyclase (QC) is described. Also described are the methods of preparing the crystalline structure of QC and the methods for identifying candidate inhibitors of QC. In addition, a structural basis for the rational design or identification of new inhibitors that may be used to treat QC-associated disorders is also described.
    Type: Application
    Filed: April 24, 2009
    Publication date: August 13, 2009
    Applicant: ACADEMIA SINICA
    Inventors: Andrew H.-J. WANG, Kai-Fa HUANG
  • Patent number: 7572614
    Abstract: A crystalline structure of glutaminyl cyclase (QC). is described. Also described are the methods of preparing the crystalline structure of QC and the methods for identifying candidate inhibitors of QC. In addition, a structural basis for the rational design or identification of new inhibitors that may be used to treat QC-associated disorders is also described.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: August 11, 2009
    Assignee: Academia Sinica
    Inventors: Andrew H.-J. Wang, Kai-Fa Huang